mercedesman wrote: Speaking of CV's
Seto's includes :
"Partner and Head of M&A at Paradigm Capital, Executive Director of M&A at UBS, and Director of M&A at CIBC World Markets where he started his investment banking career. " "see-to-it" Seto has been on board for just over 2 years now.
While there has been a significant DA negotiated, not much in the way of M&A activity to report (including RTO's and public offerings) so far. Nor much in the way of share price appreciation.
Share price was in the forties back then...now about .50.
While up 25 % in two years, not terribly impressive when one considers that Spectral should have gotten a significant boost by virtue of the fact that many Covid patients present with elevated endotoxins, die of Sepsis complications (inflammatory reaction to the virus) suffer (and die?) from excessive time on venilators, and often suffer from AKI (for which more CRRT machines are needed). Apparently KOL's, other countries are using PMX to treat Covid patients (ie. not so experimental nor just a hypothesis).
If a particular Mgt team member was somehow dead set against "pumping" a possible Covid solution (in PMX, diganotics, or AKI support) , then there should have been plenty of OTHER fodder with which to elevate the sp (ie. add shareholder value) over the past two years including:
- de-risked (Trial completion largely funded - via capital raises and Baxter)
- de-risked future revenues - via partnership with a billion dollar distribution partner
- FDA accepted a Baysian "confirmatory" Trial based on a positive result data subset (ie a revised, presumably easier to achieve, primary endpoint) and that uses Euphrates data (ie. less testing)
- FDA approval of SAMI
- advancement of DIMI towards regulatory approval
Where' the BNN interview? Where's the news dessemination in the only market that matters (and where > 90% of revenues will ultimately be derived in the future) ? Where's the widely distributed reports from multiple analysts?
If successful, share price appreciation could easily have been achieved via promotion, then the benefit is not just sp appreciation for sp appreciation sake...it would have lowered the cost of capital and reduced subsequent dilution.
The 640 M dollar multiple choice question remains. We are not pounding the table because...
(a) it's not our style..we're kind of shy about these things
(b) the Mgt team and the BoD are not up to the task.
(c) the end-game must not be share price appreciation via a US public listing
(d) all of the above
(e) none of the above.
MM